See more : Dear Life Co.,Ltd. (3245.T) Income Statement Analysis – Financial Results
Complete financial analysis of Integra LifeSciences Holdings Corporation (IART) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Integra LifeSciences Holdings Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Paras Petrofils Limited (PARASPETRO.BO) Income Statement Analysis – Financial Results
- Dollar Tree, Inc. (DT3.DE) Income Statement Analysis – Financial Results
- ULS Group, Inc. (3798.T) Income Statement Analysis – Financial Results
- Softimat S.A. (SOFT.BR) Income Statement Analysis – Financial Results
- Plantable Health Inc. (PLBLF) Income Statement Analysis – Financial Results
Integra LifeSciences Holdings Corporation (IART)
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.54B | 1.56B | 1.54B | 1.37B | 1.52B | 1.47B | 1.19B | 992.08M | 882.73M | 928.31M | 836.21M | 830.87M | 780.08M | 732.07M | 682.49M | 654.60M | 550.46M | 419.30M | 277.94M | 229.83M | 185.60M | 112.63M | 93.44M | 64.99M | 42.50M | 17.50M | 14.70M | 13.10M | 10.20M |
| Cost of Revenue | 653.18M | 587.36M | 597.81M | 520.83M | 564.68M | 571.50M | 435.51M | 349.09M | 326.54M | 352.80M | 334.09M | 314.43M | 299.15M | 268.19M | 244.92M | 252.83M | 214.67M | 168.31M | 105.54M | 87.30M | 70.60M | 45.77M | 36.01M | 26.82M | 21.80M | 6.10M | 5.20M | 4.70M | 3.50M |
| Gross Profit | 888.39M | 970.31M | 944.64M | 851.03M | 952.88M | 900.95M | 752.73M | 642.99M | 556.19M | 575.50M | 502.13M | 516.44M | 480.93M | 463.88M | 437.57M | 401.78M | 335.79M | 250.98M | 172.40M | 142.53M | 115.00M | 66.85M | 57.43M | 38.17M | 20.70M | 11.40M | 9.50M | 8.40M | 6.70M |
| Gross Profit Ratio | 57.63% | 62.29% | 61.24% | 62.03% | 62.79% | 61.19% | 63.35% | 64.81% | 63.01% | 62.00% | 60.05% | 62.16% | 61.65% | 63.37% | 64.11% | 61.38% | 61.00% | 59.86% | 62.03% | 62.02% | 61.96% | 59.36% | 61.46% | 58.74% | 48.71% | 65.14% | 64.63% | 64.12% | 65.69% |
| Research & Development | 174.59M | 101.19M | 93.05M | 77.38M | 79.57M | 78.04M | 63.46M | 58.16M | 50.90M | 51.60M | 52.09M | 51.01M | 51.45M | 48.11M | 44.28M | 60.50M | 30.66M | 25.73M | 11.96M | 14.12M | 12.81M | 8.30M | 7.99M | 7.52M | 8.70M | 8.40M | 6.40M | 6.30M | 5.20M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 690.75M | 624.10M | 455.63M | 415.76M | 445.97M | 394.25M | 373.11M | 358.13M | 305.06M | 281.10M | 281.00M | 225.19M | 157.71M | 98.27M | 99.36M | 59.46M | 40.59M | 32.37M | 43.85M | 22.20M | 15.80M | 20.30M | 9.60M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 592.64M | 616.32M | 637.45M | 594.53M | 687.60M | 690.75M | 624.10M | 455.63M | 415.76M | 445.97M | 394.25M | 373.11M | 358.13M | 305.06M | 281.10M | 281.00M | 225.19M | 157.71M | 98.27M | 99.36M | 59.46M | 40.59M | 32.37M | 43.85M | 22.20M | 15.80M | 20.30M | 9.60M | 6.10M |
| Other Expenses | 69.16M | 13.88M | 16.91M | 27.76M | 27.03M | 8.29M | 1.35M | 845.00K | 4.59M | -763.00K | -1.80M | -721.00K | 16.43M | 12.02M | 14.36M | 12.88M | 12.65M | 8.80M | 6.06M | 4.27M | 3.08M | -3.55M | 2.78M | 5.18M | 2.20M | 1.30M | 1.80M | 2.00M | 1.40M |
| Operating Expenses | 836.39M | 731.39M | 747.41M | 699.66M | 794.20M | 789.95M | 707.92M | 527.65M | 476.61M | 509.96M | 459.04M | 442.66M | 426.02M | 365.19M | 339.75M | 354.37M | 268.50M | 192.24M | 116.29M | 117.75M | 75.36M | 45.34M | 43.14M | 56.55M | 33.10M | 25.50M | 28.50M | 17.90M | 12.70M |
| Cost & Expenses | 1.43B | 1.32B | 1.35B | 1.22B | 1.36B | 1.36B | 1.14B | 876.74M | 803.15M | 862.76M | 793.12M | 757.09M | 725.17M | 633.37M | 584.66M | 607.19M | 483.17M | 360.55M | 221.83M | 205.05M | 145.95M | 91.11M | 79.16M | 83.37M | 54.90M | 31.60M | 33.70M | 22.60M | 16.20M |
| Interest Income | 17.20M | 11.92M | 6.74M | 9.30M | 10.78M | 2.80M | 255.00K | 24.00K | 13.00K | 168.00K | 443.00K | 1.21M | 465.00K | 225.00K | 631.00K | 2.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 51.38M | 49.59M | 50.40M | 71.58M | 53.96M | 64.68M | 35.02M | 25.80M | 23.52M | 21.97M | 19.79M | 22.24M | 27.64M | 18.36M | 23.23M | 30.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 123.51M | 121.12M | 123.67M | 118.99M | 114.70M | 115.70M | 88.90M | 72.67M | 9.95M | 12.40M | 47.01M | 18.54M | 16.43M | 39.17M | 39.69M | 33.15M | 27.04M | 21.48M | 13.22M | 11.59M | 9.04M | 7.16M | 6.26M | 5.18M | 2.20M | 1.30M | 1.80M | 2.00M | 1.40M |
| EBITDA | 274.01M | 391.10M | 366.33M | 267.93M | 231.03M | 241.04M | 135.23M | 231.73M | 195.59M | 172.24M | 40.07M | 116.46M | 106.31M | 139.64M | 136.07M | 79.34M | 67.29M | 58.74M | 69.33M | 36.37M | 48.69M | 25.81M | 20.54M | -13.21M | -12.40M | -16.60M | -17.20M | -7.50M | -4.60M |
| EBITDA Ratio | 17.77% | 17.77% | 15.57% | 14.06% | 13.57% | 9.73% | 5.62% | 13.11% | 10.66% | 8.33% | 10.61% | 11.17% | 9.21% | 18.86% | 20.24% | 12.44% | 16.60% | 19.61% | 25.21% | 14.08% | 14.39% | 22.91% | 15.97% | -32.65% | -34.12% | -83.43% | -130.61% | -71.76% | 144.12% |
| Operating Income | 111.53M | 238.92M | 197.23M | 151.37M | 178.98M | 111.00M | 44.80M | 115.34M | 79.59M | 65.54M | -3.64M | 73.78M | 54.91M | 98.69M | 97.82M | 47.41M | 67.29M | 58.74M | 56.11M | 24.78M | 39.65M | 19.19M | 14.29M | -18.38M | -12.40M | -14.10M | -19.00M | -9.50M | -6.00M |
| Operating Income Ratio | 7.23% | 15.34% | 12.79% | 11.03% | 11.79% | 7.54% | 3.77% | 11.63% | 9.02% | 7.06% | -0.44% | 8.88% | 7.04% | 13.48% | 14.33% | 7.24% | 12.22% | 14.01% | 20.19% | 10.78% | 21.36% | 17.04% | 15.29% | -28.29% | -29.18% | -80.57% | -129.25% | -72.52% | -58.82% |
| Total Other Income/Expenses | -30.46M | -25.03M | 17.45M | -57.85M | -33.66M | -53.60M | -33.42M | -24.93M | -18.92M | -24.88M | -21.15M | -21.75M | -26.42M | -16.58M | -24.67M | -16.41M | -7.23M | -10.44M | -1.00M | 3.23M | 3.54M | 3.54M | 1.26M | 7.54M | 7.43M | 5.26M | 2.00M | 1.90M | -19.30M |
| Income Before Tax | 81.07M | 213.89M | 214.68M | 93.52M | 60.10M | 57.40M | 11.39M | 90.41M | 60.67M | 42.98M | -24.79M | 52.03M | 28.49M | 82.11M | 73.15M | 31.01M | 60.06M | 48.31M | 55.10M | 28.01M | 43.19M | 22.73M | 15.54M | -10.85M | -7.80M | -12.30M | -17.00M | -7.60M | -25.30M |
| Income Before Tax Ratio | 5.26% | 13.73% | 13.92% | 6.82% | 3.96% | 3.90% | 0.96% | 9.11% | 6.87% | 4.63% | -2.96% | 6.26% | 3.65% | 11.22% | 10.72% | 4.74% | 10.91% | 11.52% | 19.83% | 12.19% | 23.27% | 20.18% | 16.63% | -16.69% | -18.35% | -70.29% | -115.65% | -58.02% | -248.04% |
| Income Tax Expense | 13.33M | 33.34M | 45.60M | -40.37M | 9.90M | -3.40M | -53.36M | 15.84M | 53.82M | 8.98M | -7.81M | 10.83M | 505.00K | 16.45M | 22.20M | -3.93M | 26.59M | 18.90M | 17.91M | 10.81M | 16.33M | -12.55M | -10.86M | 108.00K | -1.80M | -1.80M | -2.00M | -2.00M | 19.40M |
| Net Income | 67.74M | 180.55M | 169.08M | 133.89M | 50.20M | 60.80M | 64.74M | 74.56M | -3.52M | 34.00M | -16.98M | 41.20M | 27.99M | 65.67M | 50.96M | 34.93M | 33.47M | 29.41M | 37.19M | 17.20M | 26.86M | 35.28M | 26.16M | -11.43M | -6.00M | -12.30M | -17.00M | -7.50M | -25.40M |
| Net Income Ratio | 4.39% | 11.59% | 10.96% | 9.76% | 3.31% | 4.13% | 5.45% | 7.52% | -0.40% | 3.66% | -2.03% | 4.96% | 3.59% | 8.97% | 7.47% | 5.34% | 6.08% | 7.01% | 13.38% | 7.48% | 14.47% | 31.32% | 28.00% | -17.58% | -14.12% | -70.29% | -115.65% | -57.25% | -249.02% |
| EPS | 0.87 | 2.18 | 2.00 | 1.58 | 0.59 | 0.73 | 0.83 | 1.00 | -0.05 | 0.52 | -0.30 | 0.74 | 0.52 | 1.11 | 0.88 | 0.49 | 0.61 | 0.50 | 0.62 | 0.28 | 0.46 | 0.61 | 0.54 | -0.33 | -0.18 | -0.38 | -0.58 | -0.27 | -1.21 |
| EPS Diluted | 0.84 | 2.16 | 1.98 | 1.57 | 0.58 | 0.72 | 0.82 | 0.94 | -0.05 | 0.52 | -0.29 | 0.72 | 0.48 | 1.09 | 0.87 | 0.48 | 0.56 | 0.49 | 0.57 | 0.28 | 0.43 | 0.57 | 0.47 | -0.33 | -0.18 | -0.38 | -0.58 | -0.27 | -1.21 |
| Weighted Avg Shares Out | 78.17M | 83.00M | 84.70M | 84.65M | 85.64M | 82.86M | 78.39M | 74.72M | 73.88M | 65.48M | 56.83M | 55.90M | 53.66M | 59.10M | 58.08M | 55.56M | 55.42M | 58.60M | 60.39M | 60.13M | 58.14M | 58.04M | 46.71M | 35.11M | 33.60M | 32.28M | 29.57M | 28.11M | 20.99M |
| Weighted Avg Shares Out (Dil) | 80.34M | 83.52M | 85.49M | 85.23M | 86.49M | 84.45M | 79.12M | 79.19M | 73.88M | 65.92M | 57.60M | 57.03M | 58.99M | 60.30M | 58.58M | 56.76M | 59.16M | 65.49M | 69.13M | 62.20M | 66.21M | 61.79M | 55.59M | 35.11M | 34.12M | 32.28M | 29.57M | 28.11M | 20.99M |
Earnings Preview: Integra LifeSciences (IART) Q4 Earnings Expected to Decline
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra LifeSciences to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
PRINCETON, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, prior to the market open. In conjunction...
Here's Why Investors Should Retain Integra (IART) Stock Now
Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.
Integra LifeSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president and chief executive officer will present at the 42nd Annual J.P. Morgan Healthcare conference on January 10,...
Integra (IART) to Advance ENT Division With New Buyout Deal
Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.
Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent®
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced that it has entered into a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a Johnson &...
Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors
PRINCETON, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company's board...
Integra Gains From New Product Launches, Mounting Costs Ail
Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.
Why Is Integra (IART) Up 10.2% Since Last Earnings Report?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Integra Investors of a Lead Plaintiff Deadline of November 13, 2023
NEW YORK , Nov. 13, 2023 /PRNewswire/ -- Attention Integra LifeSciences Holdings Corporation ("Integra") (NASDAQ: IART) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 11, 2019...
Source: https://incomestatements.info
Category: Stock Reports